secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001724521-26-000032
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q1 net loss $128M, cash $876M; discontinues Phase 3 STAR-121 in NSCLC
---------------------------------------------------------------------------

- Net loss $128M for Q1 2026 vs $112M Q1 2025; revenue $17M down from $28M.
- Cash $876M at Mar 31, 2026, down from $1.0B at Dec 31, 2025; expect ~$600M year-end, runway to H2 2028.
- Discontinued Phase 3 STAR-121 (domvanalimab) in NSCLC after futility analysis (OS not improved vs pembrolizumab+chemo).
- Pipeline: casdatifan Phase 3 PEAK-1 enrolling; 1L Phase 3 initiation expected year-end; new I&I candidate AB102 entering clinic Q3 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/0001724521-26-000032-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452126000032/rcus-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001724521-26-000032

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer